Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Abbott Laboratories (NY: ABT )

118.77 -0.18 (-0.15%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
40 41 Next >
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' < 
Via Benzinga
Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices
The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as  
Via Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
Via Benzinga
Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories
A New York City woman has reportedly sued Abbott Laboratories (NYSE: ABT), accusing them of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase... 
Via Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
Via Benzinga
Abbott Laboratories Unusual Options Activity For May 10
Via Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
Via Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
Got $1,000? 2 Top Dividend Stocks to Buy Now
Passive income can add to your stock market winnings. 
Via The Motley Fool
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks
Here are seven must-have dividend stocks for long-term investing that you can consider for your dividend stock portfolio. 
Via InvestorPlace
Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest'
Via Benzinga
3 Dividend Stock Warning Signs That Could Portend Trouble
Recognizing these red flags will help you avoid investing in weaker businesses. 
Via The Motley Fool
Is Dexcom a Good Stock to Buy Now?
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it. 
Via The Motley Fool
3 Stocks to Buy Before They Soar to New Heights in 2023
Here are three stocks to buy, for investors looking for companies on the cusp of a potential breakout driven by secular growth catalysts. 
Via InvestorPlace
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
Via Benzinga
Is Abbott Laboratories Stock a Buy for Dividend Investors?
This healthcare company stands out among its peers as a Dividend King. 
Via The Motley Fool
Abbott Laboratories Unusual Options Activity
Via Benzinga
Why Abbott Laboratories Stock Looks Ridiculously Overpriced
Abbott's stock is trading at a huge premium, and it isn't a justifiable one for investors. 
Via The Motley Fool
Can Boston Scientific Set Another Net High?
Boston Scientific issued a stellar report and gave favorable guidance, but the stock is having difficulty moving higher and may move sideways in the near term. 
Via MarketBeat
7 Healthcare Stocks With Huge Return Potential for Long-Term Investors
These leading healthcare companies have proven that they can deliver reliable gains to their shareholders over many years and decades. 
Via InvestorPlace
The Fed Predicts a Recession: Should You Still Buy Stocks Now?
The Fed expects a "mild" downturn. 
Via The Motley Fool
Sleep Easy With These 2 Rock-Solid Dividend Stocks
They aren't in any danger of crimping their dividends. 
Via The Motley Fool
P/E Ratio Insights for Abbott Laboratories
Via Benzinga
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.  
Via Benzinga
Is Abbott Laboratories Still a Good Dividend Stock to Buy?
A better-than-expected first-quarter report already pushed it much higher. 
Via The Motley Fool
Stock Market Rally Drifts Lower; Tesla Dives On Margins; ISRG, DHI, LVS Are Winners: Weekly Review
The major indexes saw modest declines, holding in a range. 
Via Investor's Business Daily
Healthcare Sector Update: MedTech Trending Up
Earnings from major device companies and large-cap biopharma over the next two weeks will help us ascertain risks for the market. 
Via Talk Markets
Abbott Laboratories To Rally 17%? Here Are 10 Other Analyst Forecasts For Thursday
Morgan Stanley cut the price target for Charter Communications, Inc. (NASDAQ: CHTR) from $460 to $420. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Charter... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.